Which therapeutic modalities are you interested in?
Over 1,000,000 patients across randomised controlled trials, observational studies and clinical practice have been treated with the Boston Scientific BPH portfolio.¹
National and international guidelines currently support the use of these technologies
Treatments backed up on clinical evidence
How can we help you?
Abbreviations: AUASS, American Urological Association Symptom Score; BPHII, Benign Prostatic Hyperplasia Impact Index; ICS, International Continence Society; IIEF-5, International Index of Erectile Function; IPSS, International Prostate Symptom Score; Qmax, maximum quantity of urine excreted.
1. Thomas JA, Tubaro A, Barber N, et al. A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol. 2016:69(1):94–102.
2. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part II—surgical evaluation and treatment. J Urol. 2021;206(4):818–826.
3. Gravas S, Cornu JN, Gacci M, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts [Accessed April 2022].
4. NICE. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2020. Available at: https://www.nice.org.uk/guidance/mtg49. [Accessed April 2022].
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in Franc
1. Thomas JA, Tubaro A, Barber N, et al. A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol. 2016:69(1):94–102.
2. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part II—surgical evaluation and treatment. J Urol. 2021;206(4):818–826.
3. Gravas S, Cornu JN, Gacci M, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts [Accessed April 2022].
4. NICE. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2020. Available at: https://www.nice.org.uk/guidance/mtg49. [Accessed April 2022].
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in Franc